Lucid Diagnostics (LUCD) EBT Margin (2021 - 2026)
Lucid Diagnostics (LUCD) posted EBT Margin of 1069.92% for Q1 2026, up 1.47% on a QoQ basis from 1085.85% in Q4 2025, and up 217984.0% year-over-year from N/an in Q1 2025.
Lucid Diagnostics (LUCD) EBT Margin (2021 - 2026) Analysis & Trends
Lucid Diagnostics' EBT Margin history runs 6 years deep, the most recent figure standing at 1069.92% for Q1 2026.
- Quarterly EBT Margin rose 217984.0% year-over-year to 1069.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 864.1% (up 61745.0% YoY) and the FY2025 annual result came in at 1234.26%, down 18665.0% from the prior year.
- EBT Margin was 1069.92% for Q1 2026 at Lucid Diagnostics, up from 1085.85% in the prior quarter.
- Across five years, EBT Margin topped out at 369.92% in Q2 2025 and bottomed at 18880.26% in Q3 2022.
- A 5-year average of 3949.93% and a median of 1106.7% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin plunged 1540176 bps — and 2023, when it soared 1706570 bps.
- Lucid Diagnostics' EBT Margin stood at 13328.57% in 2022, then surged by 92 bps to 1041.35% in 2023, then climbed by 7 bps to 964.16% in 2024, then slipped by 13 bps to 1085.85% in 2025, then advanced by 1 bps to 1069.92% in 2026.
- Business Quant data shows LUCD's EBT Margin at 1069.92% in Q1 2026, 1085.85% in Q4 2025, and 858.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | -1,069.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,069.92% |
| Dec 31, 2025 | -1,085.85% |
| Sep 30, 2025 | -858.55% |
| Jun 30, 2025 | -369.92% |
| Mar 31, 2025 | -3,249.76% |
| Dec 31, 2024 | -964.16% |
| Sep 30, 2024 | -1,055.55% |
| Jun 30, 2024 | -1,127.56% |
| Mar 31, 2024 | -1,060.14% |
| Dec 31, 2023 | -1,041.35% |
| Sep 30, 2023 | -1,814.56% |
| Jun 30, 2023 | -7,157.86% |
| Mar 31, 2023 | -3,642.83% |
| Dec 31, 2022 | -13,328.57% |
| Sep 30, 2022 | -18,880.26% |
| Mar 31, 2022 | -6,492.06% |
| Dec 31, 2021 | -3,768.67% |
| Sep 30, 2021 | -3,478.50% |